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ABSTRACT 
Objective: The study aims to perform molecular docking to examine the interaction between propolis compound and SARS-CoV-2 main protease.  
Methods: The protein target of this research was the crystal structure of SARS-CoV-2 main protease in complex with an inhibitor N3 (PDB ID: 
6LU7). The ligand of this research was the bioactive compounds from Propolis of Tetragonula aff. biroi.  
Results: The results showed that propolis compound which has the potential to inhibit SARS-CoV-2 protease activity was Sulabiroins A (binding 
affinity-8.1 kcal/mol), following by (2S)-5,7-dihydroxy-4'-methoxy-8-prenylflavanone acid and broussoflavonol F (binding affinity-7.9 kcal/mol) 
with binding similarity more than 50% compared to N3-main protease interaction. 
Conclusion: Molecular docking showed propolis compounds of Tetragonula aff. biroi potential to inhibit SARS-CoV-2 main protease activity. The 
highest binding affinity presented by Sulabiroins A, following by (2S)-5,7-dihydroxy-4'-methoxy-8-prenylflavanone acid and broussoflavonol F, with 
values of-8.1 kcal/mol,-7.9 kcal/mol, and-7.9 kcal/mol, respectively, with binding similarity more than 50% compared to N3 and SARS-CoV-2 main 
protease interaction. 
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INTRODUCTION 
In late December 2019, there was a severe respiratory disease 
outbreak in Wuhan, China. This disease then spread to other 
country, became a global issue and declared as a pandemic by World 
Health Organization (WHO). Based on WHO’s data, almost 15.3 
million cases had been reported as of 24th July 2020 around the 
world and the amount increases every day. This disease then namely 
coronavirus disease 2019 (COVID-19). 
Coronavirus belong to Coronaviridae family and Orthocoronavirinae 
subfamily [1]. Coronavirus is an enveloped virus with positive single 
stranded RNA. In 2003, there was associated case, namely severe acute 
respiratory syndrome (SARS-2003), caused by another beta-
coronavirus. Another case related coronavirus was Middle East 
Respiratory Syndrome (MERS) in 2012. Both SARS-2003 and MERS 
were caused by coronavirus, the difference was the objects which 
transmitted the virus. SARS was transmitted from exotic animals in wet 
markets to humans, whereas MERS is transmitted to humans from 
camels [2]. 
Epidemiological investigations then revealed that COVID-19 was 
caused by severe acute respiratory syndrome coronavirus (SARS-
CoV-2) [3]. The exact origin, location, and natural host of SARS-CoV-
2 is not clear. COVID-19 causes nonspecific symptoms, including 
fever, dry cough, and fatigue. Many systems may be involved, such as 
respiratory system (sore throat, short of breath, cough, rhinorrhea, 
hemoptysis, and chest pain), gastrointestinal system (nausea, 
diarrhea, and vomiting), musculoskeletal system (muscle ache), and 
neurologic system (headache or confusion) [4]. 
Currently, there is no validated therapy and no vaccine available for 
COVID-19. Some treatments are underway, including antiviral drug 
development for Ebola and SARS as COVID-19 treatment, using COVID-
19 patient’s plasma as convalescent therapies. But further trial needed 
to evaluate the effectiveness of those therapies [5]. Experimental trial 
needed to find safe and effective therapy for COVID-19 patients. 
According to several reports, propolis have several biological 
activities, including antioxidant, anti-inflammatory, antifungal, and 
antiviral [6–9]. Propolis is a natural resinous substance collected by 
honey bees from buds and exudates of plant species, mixed with bee 
enzymes, pollen and wax. The chemical composition of the propolis 
biologically active compounds depends on the geographical and 
botanical origin, the type of bees, and the seasons in which propolis 
is collected [10]. Several compounds within propolis have been 
identified, including flavonoids, terpenes, phenols and their esters, 
sugars, hydrocarbons and mineral elements [11]. 
Sabanovic et al., (2019) revealed that propolis have antiviral activity [9]. 
It acts at different levels and blocks the replication of certain viruses such 
as herpes simplex type 1 and 2, adenovirus type 2, influenza virus, 
human immunodeficiency virus (HIV), and others. Furthermore, Yildirim 
et al., (2016) reported that Hatay propolis may be a potential drug for 
the Herpes Simplex Virus infections treatment [11]. The combination 
between Hatay propolis and acyclovir (standard drug) produce a 
stronger antiviral effect against HSV-1 and HSV-2 than acyclovir alone. 
Research by Banskota et al. (2001) showed that propolis can exhibit 
antiviral activity by causing partial blocking of viral penetration into the 
cell, affecting the steps in the viral replication cycle, and leading to 
degradation of the RNA virus before penetration in a cell or after its 
release into the supernatant [12]. 
Since the target protein is known, computational study can be operated 
to determine SARS-CoV-2 potential drug [11, 14]. The study of Yu et al., 
(2020) found that molecular docking can be used to identify SARS-CoV-2 
potential drug that has antiviral activity [1, 3]. It revealed that the main 
flavonoid of honeysuckle, luteolin can bind to the active sites of the 
SARS-CoV-2 main protease tightly with lower binding energy than the 
ligand of the protein crystal structure. Furthermore, molecular docking 
can be conducted to analyze the propolis compound that has antiviral 
activity and potential to be SARS-CoV-2 drug. Molecular docking is a 
computational procedure that tries to predict a macromolecule 
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(receptor) and a small molecule (ligand) noncovalent binding, so bound 
conformations and the binding affinity can be determined [13]. 
This research aims to examine the potential propolis compounds of 
Tetragonula aff. biroi as COVID-19 therapy by molecular docking. 
The protein target of this research is the crystal structure of SARS-
CoV-2 main protease in complex with an inhibitor N3 (PDB ID: 
6LU7). There is already an inhibitor in its active site. The ligand of 
this research is the bioactive compounds from propolis of 
Tetragonula aff. biroi. Bioactive compounds of propolis believed can 
interact with the crystal structure of SARS-CoV-2 main protease. To 
determine it, molecular docking is used to identify which 
compounds are bound into the binding site. The potential propolis 
compounds show the lowest molecular docking score toward SARS-
CoV-2 main protein.  
MATERIALS AND METHODS 
Hardware instrument 
Specification of laptop in this research is Acer Aspire V5, AMD C-70 
APU with Radeon™ HD Graphics 1.00 GHz processor, 2.00 GB of 
RAM. Windows 8 Pro 32-bit Operating System, x64-based processor. 
Software instrument 
The software used in this research are Visual Molecular Dynamic 
(VMD, University of Illinois, Urbana-Champaign), PyMOL, Autodock 
Tools 1.5.6 (The Scripps Research Institute, USA), Autodock Vina 
(The Scripps Research Institute), MarvinSketch (ChemAxon, 
Budapest, Hungary), and LigPlot+(EMBL-EBI, UK). 
Propolis compounds selection  
According to Miyata et al., (2020), various compounds were 
identified from the propolis of stingless bees (Tetragonula aff. biroi) 
(table 1, Compound 1-13) [16, 17]. Meanwhile, Mahadewi et al. 
(2018) reported that Sulawesi propolis wax contained antifungal 
compounds (table 1, Compound 14-17) [18]. Furthermore, Sahlan et 
al. (2019) identified anti-inflammatory compounds from propolis of 
Tetragonula sp., (table 1, Compound 18-20) [7]. 
Protein structure preparation 
The crystal structure of the examined protein was downloaded from 
RCSB Protein Data Bank (http://www.rcsb.org) in the PDB format. 
In this study, we obtain the crystal structure of SARS-CoV-2 main 
protease in complex with an inhibitor N3 (PDB ID: 6LU7). The 
protein and native ligand then separated using VMD (Hsin et al., 
2008), in this case, the native ligand is N3 [20]. The separated file 
was saved as*. pdb. These files are then loaded to Autodock Tools 
1.5.6 to prepare the 3D structure of each protein and native ligand 
as*. pdbqt file format. The protein preparation, including the 
addition of polar hydrogens and charges. 
 
Table 1: Propolis compounds 
No Compound Molecular formula Structure-2D 
1 Sulabiroins A C22H22O7 
 






4 (-)-Papuanic acid C25H36O6 
 
5 (–)-Isocalolongic Acid C24H34O6 
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6 Isopapuanic acid C25H36O6 
 
7 Isocalopolyanic acid C24H32O6 
 
8 Glyasperin A C25H26O7 
 
















14 Curcumene C15H22 
 
15 Thymol C10H14O 
 
16 Tetralin C10H12 
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17 P-Coumaric acid C9H10O3 
 
18 α-Tocopherol succinate C32H52O5 
 
19 Deoksi podophyllotoxin C22H22O7 
 
20 Xanthoxyletin C15H14O4 
 
 
Ligand structure preparation 
In total 21 ligands used in this research, one native ligand as a 
control (fig. 1) and 20 propolis compounds (table 1). 
 
 
Fig. 1: Structure of native ligand N3 (http://www.rcsb.org) 
 
The 2D structure of propolis compounds prepared by using Marvin 
Sketch (Csizmadia, 1999) and converted into 3D structure [21]. All 
files then saved as*. pdb format and loaded to Autodock Tools 1.5.6 
to prepare*. pdbqt file by adding polar hydrogens and charges. 
Re-docking 
Docking propolis compounds, as a ligand, to the main protease 
required specific search space. This is the important step to 
determine the binding site of the ligand within the protein area, 
hence re-docking have to be done. This step involves separating 
native ligand and protein then dock it back to its place on protein by 
setting the size and the center of the search space box [22]. Re-
docking and docking simulation performed by AutoDock Vina, 
automated docking tools with easy operational use, high processing 
speed and binding mode prediction accuration [15]. Autodock Vina 
was chosen because of its accuracy is higher than Autodock Tools in 
term of binding mode predictions [23]. 
Determining the specific search space in protein involves three 
criterions; number of points in x, y, z dimension (grid box size), grid 
box center and grid spacing. Re-docking simulation obtain some 
poses, the first generally poses the best pose with the lowest docking 
score. Then Root Mean Square Deviation (RSMD) between native 
ligand and re-docking result first pose was evaluated using PyMol, 
Python-based software that can be used for protein-ligand modelling 
[24]. The result is classified as the accurate one if the RSMD value is 
less than 2 Å [25]. The re-docking coordinate then used to dock 
propolis compounds into the protein target. 
Docking and analysis 
Propolis compounds were docked to each receptor using parameters 
and coordinates that had been obtained from re-docking simulation. 
The lowest docking score result was considered as the best pose 
which used to analyze the interaction between propolis compounds, 
as a ligand, and protein. The interaction profiles then represented in 
2D visualization using LigPlot+. LigPlot+is an automatic program 
that generates multiple two-dimensional (2D) diagrams of ligand–
protein interactions from docked complexes. It is utilized to identify 
the interacting residues, hydrogen bonds interaction, and 
hydrophobic contacts of ligands and the main-chain or side-chain of 
the protein [26].  
RESULTS AND DISCUSSION 
Selection of propolis compound 
This study focused on identifying propolis compounds of 
Tetragonula aff. biroi that targeted the main protein (Mpro) of SARS-
CoV-2. Mpro is a 33.8-kDa protease, it is a coronaviruses key enzyme 
and has a pivotal role in mediating viral replication and 
transcription functions through extensive proteolytic processing of 
two replicased polyproteins, pp1a (486 kDa) and pp1ab (790 kDa) 
(Yang et al., (2003). Its important role makes it an interesting target 
for developing SARS-CoV-2 potential drugs. From several main 
protease structures which available at Protein Data Bank, PDB ID 
6LU7 was chosen in this research because it has native ligand N3 
that bind to the substrate-binding pocket of SARS-CoV-2 main 
protease. Jin et al., (2020) found that N3 showed inhibition activity 
against SARS-CoV-2 with individual half-maximal effective 
concentration (EC50) values of 16.77 µM. 
The selection of 20 propolis compounds in table 1 based on previous 
researches that have been done.  
 
Table 2: Parameter optimization by re-docking simulation 
Coordinates Grid box size (Å) Grid box center Grid spacing (Å) 
x 22 -13.939 1 
y 24 12.912 
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z 26 69.026 
 
Binding site determination 
Binding site then became an area where the propolis compounds 
bind to the protein. Native ligand re-docking obtained mode 1 as the 
best pose, which had a docking score-8.4 kcal/mol. The grid box was 
determined on the active site area, considering the presents of 
amino acids Thr190, Glu166, Gln189, Gln192, Gly143, His163, 
His172, His164, Cys145, Phe140, Phe185, accordance to previous 
studies with the crystallographic structure of the SARS-CoV-2 main 
protease [27, 28]. Re-docking evaluation performed by 
calculating Root-Mean Square Deviation (RMSD) value using 
Pymol and the result was 1.468 Angstroms. Meanwhile, 
Andrade et al. (2020) reported that the best confirmation of N3 
presented RMSD of 1.94 Angstroms (fig. 2b) [29]. Fig. 2 shows 
the comparison position between crystallized N3 and re-
docking confirmation result. 
First, re-docking done by AutoDock Vina where the native ligand 
was docked back to protein in specific area so the binding site can be 
determined. Re-docking simulation found that the binding site 
apparently located at the following coordinate (table 2). 
RMSD was used to validate the docking procedure. It represents the 
difference between the acquired docking pose and the crystallized 
ligand orientation of the same ligand molecule. The criterion of the 
correct orientation often uses RMSD ≤ 2Å [25]. The lower RMSD 
value, the docking pose getting more similar to crystallized ligand 
orientation. It means the docking procedure is validated and its 
accuracy getting higher. 
 
 
(a)     (b) 
Fig. 2: Comparison position between crystallized N3 (yellow) and re-docked N3 (cyan), (a) research result position, (b) Andrade et al., 
(2020) report 
 
Docking procedure results of propolis compounds 
Molecular docking performed by AutoDock Vina obtain 9 ligand 
poses with different docking score. AutoDock Vina determines the 
docking score, also known as binding affinity, automatically [15]. 
The lowest docking score represented the strongest binding affinity. 
Docking score results of propolis compounds towards SARS CoV-2 
main protease in complex with an inhibitor N3 showed by table 3. 
The results present that all compounds bind to amino acid at binding 
site. The propolis compound which has the lowest docking score was 
Sulabiroins A, following by (2S)-5,7-dihydroxy-4'-methoxy-8-
prenylflavanone and broussoflavonol F, with values of-8.1 kcal/mol,-
7.9 kcal/mol, and-7.9 kcal/mol, in succession.  
Propolis and SARS-CoV-2 main protease interaction 
The interaction between propolis compounds and main protease 
then analyzed using LigPlot+. The visualization results of three 
propolis compounds with the lowest docking score are presented in 
fig. 3. There are two kinds of molecular interactions in the 
visualization result; dashed lines and arcs. The green dashed lines 
illustrate hydrogen bonds, the length of the bond showed by the 
numbers above these lines. Meanwhile, the arcs with spokes 
radiating toward the ligand atoms mean hydrophobic interactions. 
Furthermore, ligand structure is represented by purple lines and 
amino acid residues showed by the brown line. 
 
Table 3: Docking result of propolis compounds towards SARS CoV-2 main protease 
No Propolis compounds Docking score 
1 N3 (native ligand) -8.4 
2 Sulabiroins A -8.1 
3 Broussoflavonol F -7.9 
4 (2S)-5,7-dihydroxy-4'-methoxy-8-prenylflavanone -7.9 
5 Sulabiroins B -7.8 
6 Glyasperin A -7.8 
7 Deoksi podophyllotoxin -7.4 
8 Papuanic acid -7.4 
9 Isorhamnetin -7.3 
10 Isocalolongic acid -7.2 
11 2',3'-dihydro-3'-hydroxypapuanic acid -7.1 
12 Isopapuanic acid -7.0 
13 Xanthoxyletin -6.7 
14 (1'S)-2-trans,4-trans-abscisic acid -6.5 
15 Isocalopolyanic acid -6.4 
16 α-Tocopherol succinate -6.2 
17 (1'S)-2-cis,4-trans-abscisic acid -6.0 
18 Curcumene -5.5 
19 P-coumaric acid -5.1 
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20 Tetralin -4.7 
21 Thymol -4.7 
 
Molecular interaction between amino acid residues of main protease 
with various ligand represents in table 4. Native ligand N3 formed 
hydrogen bond with Thr190, Gln189, His41, Ser144, His163, Glu166 
and Phe140. Yu et al., (2020) reported that N3 formed a hydrogen 
bond with Cys145 and Gln189 [30]. N3 also formed hydrophobic 
interaction with Thr25, Leu27, Leu4, Val3, and Asn142.  
The interaction between the three best propolis compounds with 
SARS-CoV-2 main protease indicated that each compound has a 
bound to binding site in the main protease. It is enhanced by the 
binding similarity result that represents each propolis compound 
has a similarity above 50% compared to N3 and SARS-CoV-2 main 
protease interaction. Compared with N3–main protease interaction, 
the interaction of Sulabiroins A, Broussoflavonol F, and (2S)-5,7-
dihydroxy-4'-methoxy-8-prenylflavanone with main protease 
represented the binding similarity of 64%, 59%, and 59%, 
respectively. 
Sulabiroins A did not form hydrogen bond with any residues. It 
formed hydrophobic interaction with 14 amino acids in the active 
site region of SARS-CoV-2 main protease instead. Broussoflavonol F 
represented hydrogen bond with the residues Cys145, Gly143, 
Gln189, His163, Leu141 and Ser144. Furthermore, (2S)-5,7-
dihydroxy-4'-methoxy-8-prenylflavanone displayed five hydrogen 
interactions with Ser144, Leu141, Gly143, Glu166 and Asp187. It 
showed interaction with Leu27, which did not interact with other 
propolis compounds, including N3. 
 
 
(a)      (b) 
 
(c)     (d) 
Fig. 3: Interaction visualization of main protease with various ligands. (a) N3; (b) Sulabiroins A; (c) Broussoflavonol F; (d) (2S)-5,7-
dihydroxy-4'-methoxy-8-prenylflavanone 
 
Table 4: Molecular interaction of various ligands and main protease 
Ligand Binding analysis  Interactions with 
other residues Hydrogen bonding Hydrophobic interactions Binding 
similarity* 
N3 (native ligand) Thr190, Gln189, His41, Pro168, Ala191, Leu167, Arg188, Met49, 100% - 
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Ser144, His163, Glu166, 
Phe140 
Thr24, Asp187, Thr25, Thr26, Cys145, 
His164, Gly143, Asn142, Leu141, Met165 
Sulabiroins A - Asp187, His41, Gln189, Met49, Thr25, 
Gly143, Cys145, Leu141, His163, Ser144, 
His164, Met165, Glu166, Arg188 
64% - 
Broussoflavonol F Cys145, Gly143, Gln189, 
His163, Leu141, Ser144 





Ser144, Leu141, Gly143, 
Glu166, Asp187 
Asn142, His41, Met49, Gln189, Met165, 
His164, Arg188, Cys145 
59% Leu27 
*Binding similarity between propolis compounds–protease interaction and inhibitor N3–protease interaction 
Jin et al., (2020) reported that SARS-CoV-2 Mpro has a Cys-His 
catalytic dyad, and the substrate-binding site is located in a cleft 
between domain I (residues 8–101) and domain II (residues 102–
184) [27]. This is supported by Hsu et al., (2005) that the active site 
of SARS-CoV-2 main protease SARS-CoV consisting of His41 and 
Cys145 [31]. Sulabiroins A and (2S)-5,7-dihydroxy-4'-methoxy-8-
prenylflavanone have hydrophobic interaction His41 and Cys145. 
Meanwhile, Broussoflavonol F only has one hydrogen bonding with 
Cys145. Since His41 and Cys145 were known as catalytic site, so 
these three propolis compounds potential to inhibit main protease 
activity.  
Further studies are needed to determine the efficacy and safety of 
these propolis compounds for COVID-19 therapy. There are 
numerous drugs and ongoing medication strategies under clinical 
trials related with COVID-19 with a hope for avoiding possible 
threatening of the lives of millions of human beings and providing 
directions for future research. 
CONCLUSION 
Molecular docking showed propolis compounds of Tetragonula aff. 
biroi potential to inhibit SARS-CoV-2 main protease activity. The 
highest binding affinity presented by Sulabiroins A, following by (2S)-
5,7-dihydroxy-4'-methoxy-8-prenylflavanone and broussoflavonol F, 
with values of-8.1 kcal/mol,-7.9 kcal/mol, and-7.9 kcal/mol, 
respectively, with binding similarity more than 50% compared to N3 
and SARS-CoV-2 main protease interaction. These three compounds 
could be a promising drug candidate for COVID-19 as they interacted 
with His41 and Cys145 in the active site of SARS-CoV-2 main 
protease. Further studies are needed to determine the efficacy and 
safety of these propolis compounds for COVID-19 therapy [32]. 
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